Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study

Am Rev Respir Dis. 1976 Sep;114(3):471-5. doi: 10.1164/arrd.1976.114.3.471.


A comparison has been made of the relapse rates between 7 and 30 months for four 6-month regimens. Streptomycin plus isoniazid plus rifampicin had a relapse rate of 2 per cent of 171 patients; isoniazid plus rifampicin had a relapse rate of 7 per cent of 164. An initial 2 months of streptomycin, isoniazid, rifampicin, and pyrazinamide, when followed by thiacetazone plus isoniazid, had a relapse rate of 7 per cent of 179, and when followed by streptomycin plus isoniazid plus pyrazinamide twice a week the relapse rate was 4 per cent of 159 patients. Of the 36 relapses, 32 occurred in the first 6 months after stopping chemotherapy and 35 were with drug-susceptible organisms. The difference between the relapse rate on the streptomycin plus isoniazid plus rifampicin regimen and the isoniazid plus rifampicin and thiacetazone plus isoniazid regimens approached significance (P =0.06 for both comparisons).

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Isoniazid / analogs & derivatives
  • Isoniazid / therapeutic use*
  • Isoniazid / urine
  • Pyrazinamide / therapeutic use*
  • Rifamycins / therapeutic use*
  • Streptomycin / therapeutic use*
  • Time Factors
  • Tuberculosis, Pulmonary / drug therapy*


  • Rifamycins
  • Pyrazinamide
  • Isoniazid
  • Streptomycin